UBS analyst Ashwani Verma lowered the firm’s price target on Neurocrine (NBIX) to $137 from $154 and keeps a Buy rating on the shares. The stock represents an attractive risk/reward in the current biotech climate, particularly as the preference for commercial names increases, the analyst tells investors in a research note. The firm notes that Neurocrine does not have any regulatory exposure for the next year-plus, and says Q1 appears “far less crowded” as opposed to 4Q24 earnings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Market Position and Growth Potential Justify Buy Rating Amid Challenges
- Neurocrine price target raised to $184 from $183 at JPMorgan
- Neurocrine’s ingrezza shows efficacy in tardive dyskinesia study
- Neurocrine presents new KINECT-HD data
- Neurocrine price target lowered to $139 from $148 at RBC Capital